Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Drug clearance

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    2,062 result(s) found for: Drug clearance. Displaying page 13 of 104.
    EudraCT Number: 2014-004161-24 Sponsor Protocol Number: A0221066 Start Date*: 2015-03-24
    Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, NY 10017
    Full Title: An Open-Label, Dose-Escalating Study of the Pharmacokinetics, Safety and Tolerability of Fesoterodine in Pediatric Overactive Bladder Patients Aged 8-17 Years
    Medical condition: Overactive bladder (OAB) and Neurogenic Detrusor Over activity
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-001515-37 Sponsor Protocol Number: C-II-005 Start Date*: 2008-06-11
    Sponsor Name:CESAR Central European Society for Anticancer Drug Research
    Full Title: A prospective angiogenic imaging study with DCE-MRI and DCE-USI in patients with colorectal cancer and liver metastases receiving sunitinib in addition to 5-FU, folinic acid and irinotecan (FOLFIR...
    Medical condition: metastatic colorectal carcinoma with liver metastases
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052358 Colorectal cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-004983-30 Sponsor Protocol Number: ACO-ASSO LM1 Start Date*: 2006-11-03
    Sponsor Name:ACO-ASSO
    Full Title: Pre- and postoperative chemotherapy including Bevacizumab in potentially curable metastatic colorectal Cancer (mCRC). A multicenter, prospective Phase I/II academic trial.
    Medical condition:  Patients with histologically confirmed diagnosis of metastatic Colorectal Cancer (CRC) including potentially resectable liver metastases, untreated yet with chemotherapy for metastatic disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002258-60 Sponsor Protocol Number: UMCN-ONCO-201302 Start Date*: 2013-08-30
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: prediction of everolimus-induced interstitial lung disease in breast cancer patients; maximizing efficacy by reducing toxicity
    Medical condition: breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults Gender: Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-006465-85 Sponsor Protocol Number: BENEFIX Start Date*: 2009-09-10
    Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA CAREGGI
    Full Title: Pharmacokinetic evaluation of a new formulation of recombinant factor IX (BeneFIX) in the italian population with severe or moderate B haemophilia previously treated.
    Medical condition: Patients with severe or moderate B Haemophilia, previously treated with rFIX.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010331 SOC
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-000026-31 Sponsor Protocol Number: ML18704 Start Date*: 2006-06-20
    Sponsor Name:Roche Austria GmbH
    Full Title: Bevacizumab as treatment for patients with relapsed/refractory multiple myeloma
    Medical condition: Multiple myeloma, relapsed/refractory after at least 2 lines of prior therapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-003978-10 Sponsor Protocol Number: INT/ISS 1 Start Date*: 2006-10-31
    Sponsor Name:ISTITUTO SUPERIORE DI SANITA'
    Full Title: Pilot Study with fixed dose of Cisplatinum in combination with esomeprazole (dose-ranging) as salvage treatment in patients with pre-treated advanced/methastatic melanoma
    Medical condition: Patient with metastatic melanoma (stage IV)
    Disease: Version SOC Term Classification Code Term Level
    6.1 10025671 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-006718-13 Sponsor Protocol Number: R0452 Start Date*: 2007-10-11
    Sponsor Name:Hull and East Yorkshire NHS Trust
    Full Title: Opioids in the management of breathlessness in chronic heart failure
    Medical condition: Patients known to the Academic Unit of Cardiology that have symptomatic chronic heart failure (New York Heart Association grading 3-4) despite maximal medical treatment.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-004925-64 Sponsor Protocol Number: Cola Start Date*: 2008-05-28
    Sponsor Name:HSK Research GmbH
    Full Title: A Phase II Controlled Study of pegylated liposomal Doxorubicin (PLD, CAELYX) and Carboplatin for the Preoperative Treatment of Advanced Breast Cancer
    Medical condition: A PLD and Carboplatin based neoadjuvant treatment regimen with less cardiotoxicity (as compared to other anthracyclines) and generally reduced side effects is of interest not only for breast cancer...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-000987-11 Sponsor Protocol Number: 2012/409 Start Date*: 2012-07-02
    Sponsor Name:Anni Ravnbek Jensen
    Full Title: DEBIRI-TACE (DRUG ELUTING BEAD med IRINOTECAN-TRANS ARTERIEL CHEMO EMBOLIZATION) Intrahepatic chemoembolization with irinotecan-containing DC-BEADS combined with systemic chemotherapy and bevac...
    Medical condition: Metastatic colorectal cancer with metastasis confined to the liver
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-002395-41 Sponsor Protocol Number: 309100 Start Date*: 2004-12-03
    Sponsor Name:Schering AG
    Full Title: Phase II study of MS-275, a histone deacetylase inhibitor, comparing 2 dosage schedules in patients with metastatic melanoma
    Medical condition: Metastatic malignant melanoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-001539-23 Sponsor Protocol Number: PET_ONKO Start Date*: 2006-06-07
    Sponsor Name:department of clinical pharmacology
    Full Title: Does imatinib therapy lead to an increased uptake of low molecular weight substances into solid tumor metastasis in patients with hormone refractory prostate cancer?
    Medical condition: patients with HRPC and bone metastases will be enrolled in the study
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-001555-19 Sponsor Protocol Number: HE 2D07 Start Date*: 2008-02-26
    Sponsor Name:Hellenic Cooperative Oncology Group
    Full Title: DOCETAXEL COMBINED WITH PULSATILE ERLOTINIB (TARCEVA) IN PATIENTS WITH METASTATIC NON SMALL CELL LUNG CANCER (NSCLC)
    Medical condition: Metastatic (stage IV) non-small cell lung cancer (NSCLC) who have not previously been treated with anticancer drugs
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-003723-21 Sponsor Protocol Number: BSMO-2014-01 Start Date*: 2015-05-27
    Sponsor Name:Belgian Society of Medical Oncology
    Full Title: A prospective, Belgian multi-center, single-arm, phase II study of neoadjuvant weekly paclitaxel and carboplatin followed by dose dense epirubicin and cyclophosphamide in stage II and III triple ne...
    Medical condition: Stage II and III triple negative breast cancer patients suitable for preoperative chemotherapy
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-000815-24 Sponsor Protocol Number: 01-2006 Start Date*: 2006-07-28
    Sponsor Name:Charité
    Full Title: A randomized study of topical 3% Diclofenac in a 2.5% Hyaluronate base (Solaraze® 3% Gel) versus topical 5% 5-Fluorouracil (Efudix® Cream) versus liquid nitrogen spray cryotherapy in immunosufficie...
    Medical condition: Actinic keratosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-000034-36 Sponsor Protocol Number: CHDR1734_CLS003-CO-PR-004 Start Date*: 2018-08-10
    Sponsor Name:Cutanea Life Sciences
    Full Title: A phase 2, randomized, double blind, vehicle controlled, parallel group study to explore the efficacy, pharmacodynamics and safety of topical ionic contra-viral therapy (ICVT), comprised of digoxin...
    Medical condition: Actinic keratosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10000614 Actinic keratosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2009-011324-60 Sponsor Protocol Number: DE-09-RG-53 Start Date*: 2009-07-07
    Sponsor Name:Hannover Medical School
    Full Title: Prospective randomized trial to compare a twice daily to a once daily administration of the Tacrolimus in lung transplanted patients
    Medical condition: Patients ( ≥18 and ≤ 70 years) ≥ 1 year after single, double or heart/lung transplantation.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003558-98 Sponsor Protocol Number: CHDR1939 Start Date*: 2020-02-10
    Sponsor Name:Centre for Human Drug Research
    Full Title: Randomized, double-blind, placebo-controlled, two way crossover, single centre study evaluating the acute and chronic effect of clonazepam on cognitive tests and patient-reported outcome measures i...
    Medical condition: ARID1B-related intellectual disability
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000830-68 Sponsor Protocol Number: BO39813 Start Date*: 2018-03-19
    Sponsor Name:F. Hoffman-La Roche Ltd.
    Full Title: A PHASE IB/II STUDY OF COBIMETINIB ADMINISTERED AS SINGLE AGENT AND IN COMBINATION WITH VENETOCLAX, WITH OR WITHOUT ATEZOLIZUMAB, IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA
    Medical condition: Multiple Myeloma (MM)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DK (Completed) SE (Completed) DE (Completed) CZ (Completed) ES (Completed) FR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-004946-13 Sponsor Protocol Number: Taglumet Start Date*: 2020-08-20
    Sponsor Name:Univeristy Hospital Tuebingen
    Full Title: Conversion to extended-release MeltDose® tacrolimus after kidney transplantation - impact on glucose metabolism and lipid profile
    Medical condition: stable adult kidney transplant
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jul 16 10:13:47 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA